telmisartan + levamlodipine + rosuvastatin

CKD-346 is a fixed-dose triple combination (FDC) therapy developed by Chong Kun Dang Pharmaceutical for the concurrent management of hypertension and hyperlipidemia. The drug contains three active ingredients: telmisartan, an angiotensin II type 1 receptor antagonist (ARB); levamlodipine (the S-enantiomer of amlodipine), a dihydropyridine calcium channel blocker (CCB); and rosuvastatin, an HMG-CoA reductase inhibitor (statin). By targeting both the renin-angiotensin-aldosterone system and L-type calcium channels, the combination provides dual-mechanism blood pressure control, while the inclusion of rosuvastatin addresses comorbid dyslipidemia. This triple combination is designed to simplify complex treatment regimens for patients with multiple cardiovascular risk factors, thereby improving medication adherence and clinical outcomes. Levamlodipine is utilized specifically to provide the antihypertensive benefits of amlodipine with a potentially lower incidence of peripheral edema.

Brand names

Telminuvo R

Other names

Telmisartan/S-amlodipine/RosuvastatinTelmisartan/Levamlodipine/RosuvastatinCKD-828 + Rosuvastatin